期刊文献+

2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物的合成与抗焦虑活性研究 被引量:1

Synthesis and anxiolytic effects of 2-aryl imidazo[1,2-a]pyridine-3-acetamide derivatives
下载PDF
导出
摘要 目的寻找水溶性较好、抗焦虑活性较强的新型化合物。方法设计合成2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺类化合物,通过体外苯二氮受体竞争结合实验及小鼠高架迷宫行为实验,评价化合物的体内外抗焦虑活性,分析化合物的构效关系。结果与结论共合成28个新型化合物,通过1H-NMR和MS确证其结构,其中I8和I10水溶性良好。苯二氮受体竞争结合实验结果表明,化合物Ⅰ1、Ⅰ8、Ⅰ10、Ⅰ13、Ⅰ19与苯二氮受体的亲和力与阳性对照药物Ro5-4864相当,在浓度为100nmol/L时,其对放射性配体与受体结合的抑制率分别为87%、89%、85%、89%和76%,而Ro5-4864为82%。对水溶性及活性均较好的化合物Ⅰ和Ⅰ进行小鼠抗焦虑活性评价结果表明,其具有明显的体内抗焦虑作用。 Objective To search for new compounds with better water-solubility and higher antianxiety activities.Methods A series of 2-arylimidazo[1,2-a]pyridine-3-acetamide derivitives were designed and synthesized.The anxiolytic activities were evaluated by BZDR competitive binding assay in vitro and the elevated-plus maze test in mice,the structure-activity relationship(SAR) has been studied.Results and Conclusion Twenty-eight new compounds have been synthesized.Their structures were confirmed by 1H NMR and MS.According to the results of BZDR affinity test,compoundsⅠ1,Ⅰ8,Ⅰ10,Ⅰ13,Ⅰ19 showed as good affinity as the positive control(Ro5-4864).The corresponding inhibition was 87%,89%,85%,89% and 76% respectively at the concentration of 100 nmol/L,while that of Ro5-4864 was 82%.Ⅰ8 andⅠ10,which display better water-solubility and better BZDR affinity in vitro,show significant antianxiety effects in vivo.
出处 《国际药学研究杂志》 CAS 2010年第4期292-301,共10页 Journal of International Pharmaceutical Research
基金 国家高技术研究发展计划(863计划)重大专项资助项目(2008ZXJ09004-032)
关键词 2-芳基咪唑并吡啶乙酰胺衍生物 TSPO配体 合成 抗焦虑作用 2-aryl imidazo[1 2-a]pyridine-3-acetamide derivatives TSPO ligands synthesis anxiolytic activities
  • 相关文献

参考文献14

  • 1陆爱军,刘冰,刘海波,周家驹.GABA_A五种亚型受体与BZ配基的3D-QSAR研究[J].物理化学学报,2004,20(5):488-493. 被引量:2
  • 2童建明,杨正春.γ—氨基丁酸亚基结构与抗焦虑催眠药物的作用机理[J].国外医学(精神病学分册),2005,32(2):74-76. 被引量:6
  • 3张瑞华,李丽琴,王惠芳,张瑞萍.A型γ氨基丁酸受体结构及其有关药物[J].生命的化学,2003,23(6):441-444. 被引量:12
  • 4周纪东,喻晓蔚.GABA_A受体的神经药理学研究进展[J].生命的化学,2002,22(2):160-162. 被引量:16
  • 5Papadopoulos V,Baraldi M,Guilarte TR,et al.Translocator protein(18 kDa):new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function[J].Trends Pharmacol Sci,2006,27(8):402-409.
  • 6Scarf AM,Ittner LM,Kassiou M.The translocator protein(18kDa):central nervous system disease and drug design[J].J Med Chem,2009,52(3):581-592.
  • 7James M,Selleri S,Kassiou M.Development of ligands for the peripheral benzodiazepine receptor[J].Curr Med Chem,2006,13(17):1991-2001.
  • 8Taliani S,Da Settimo F,Da Pozzo E,et al.Translocator protein ligands as promising therapeutic tools for anxiety disorders[J].Curr Med Chem,2009,16(26):3359-3380.
  • 9Kita A,Kinoshita T,Kohayakawa H,et al.Lack of tolerance to anxiolysis and withdrawal symp toms in mice repeatedly treated with AC-5216,a selective TSPO ligand[J].Prog Neuro-Psychoph,2009,33(6):1040-1045.
  • 10Rupprecht R,Rammes G,Eser D,et al.Translocator protein(18 kD)as target for anxiolytics without benzodiazepine-like side effects[J].Science,2009,325(5939):490-493.

二级参考文献55

  • 1[1]Collins I et al. Bioorganic & Medicinal Chemistry Letters, 2000, 10:1381-1384
  • 2[2]Ives JH et al. Journal of Neurochemistry, 2002, 80:317-327
  • 3[3]Subramaniam JR et al. Molecular Brain Research, 2001, 92:149-156
  • 4[4]Lancel M et al. Angew Chem Int Ed, 1999, 111:2852-2864
  • 5[5]Jr.L JG et al. Neuropharmacology, 2002, 42:502-521
  • 6[6]Glowa JR et al. Brain Research, 2000, 887:23-33
  • 7[7]Mehta AK et al. Brain Res Rev, 1999, 29:196-217
  • 8[8]Wingrove PB et al. Mol Pharmacol, 1997, 52:874-881
  • 9[9]Krampfl K et al. European J Pharmacology, 2002, 435:1-8
  • 10Zhou Y,国外医学,2001年,28卷,2期,69页

共引文献32

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部